Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral CSF1R inhibitor vimseltinib, newly branded Romvimza, could take significant ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- An ...

Tenosynovial giant cell tumors are not malignant but can impact patients’ quality of life, as one expert explained. There are not many patients with tenosynovial giant cell tumors, or TGCTs, with one ...

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...

These findings suggest that LIS is a reliable predictive tool for clinically relevant outcomes and response to denosumab therapy in patients with GCTB. These parameters may prove to be useful in ...

Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral CSF1R inhibitor vimseltinib, newly branded Romvimza, could take significant ...

On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in ...

The MarketWatch News Department was not involved in the creation of this content. Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III ...

A systematic analysis demonstrated the rarity of super-giant basal cell carcinomas and the need for further characterization of these understudied skin cancers. Super-giant basal cell carcinoma (SGBCC ...